Pevifoscorvir-sodium, Publications Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not -treated Subjects with Chronic HBV
Preclinical, Publications Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Preclinical, Publications CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro
Preclinical, Publications Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAg
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro
Pevifoscorvir-sodium, Publications Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184
ALG-055009, Publications A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants
Pevifoscorvir-sodium, Publications The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments